Moclobemide in Social Phobia: A Pilot Open Study

@article{Bisserbe1994MoclobemideIS,
  title={Moclobemide in Social Phobia: A Pilot Open Study},
  author={J. C. Bisserbe and Jean Pierre L{\'e}pine and G. Equinox Study Group},
  journal={Clinical Neuropharmacology},
  year={1994},
  volume={17},
  pages={S88–S94}
}
Summary: In an open‐label pilot study, 35 outpatients with social phobia (DSM‐III‐R) received moclobemide for 12 weeks. The dosing range was 300‐600 mg/day. Eighteen patients completed the study and 28 received at least 4 weeks of treatment. There was a consistent improvement in the efficacy parameters. Moclobemide was effective in both major components of social phobia (fear and avoidance). Moclobemide seems as effective as conventional irreversible monoamine oxidase inhibitors. Tolerability… Expand
Placebo-controlled trial of moclobemide in social phobia.
TLDR
Moclobemide may have efficacy in the treatment of social phobia, but absence of significant differences on most primary outcome measures and small effect sizes for all outcome measures suggest that the magnitude of its clinical effect is small. Expand
Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder
TLDR
In a large sample of social anxiety disorder patients with and without comorbid anxiety disorders, moclobemide was both effective and well-tolerated in the short as well as long-term, and strengthen the range of therapeutic options for managing this important disorder. Expand
Pharmacotherapy for social phobia.
TLDR
Evidence is provided that medication can be effective in treating SP over the short term, with the strongest evidence of treatment efficacy observed amongst the SSRIs. Expand
Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia.
TLDR
CBT was highly effective in the treatment of panic disorder with agoraphobia and reduced agorAPHobia to levels that were comparable to those of non-clinical controls. Expand
Social Anxiety Disorder - A Review of Pharmacological Treatments
Social anxiety disorder (social phobia, SAnD) is a chronic, impairing disorder characterised by embarrassment and fear relat- ing to public scrutiny and social performance. In its generalised form itExpand
Social Phobia: Issues in Assessment and Management
TLDR
Issues to consider in the differential diagnosis of social phobia are examined, goals of treatment are reviewed, and evidence in support of the effectiveness of individual pharmacologic treatments is summarized. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Current treatments of the anxiety disorders in adults
TLDR
A brief but comprehensive review of the treatment of the five principal anxiety disorders in adults in adults with well-controlled clinical trials documenting effective pharmacological and psychological treatments. Expand
Rational antidepressant selection: applying evidence-based medicine to complex real-world patients.
TLDR
It is found that factors influencing antidepressant selection include drug factors (including tolerability, interactions, and cost), depression subtype, psychiatric and medical comorbidity, and stage of life. Expand
Moclobemide : An Update of its Pharmacological Properties and Therapeutic Use.
TLDR
Comparative studies have established that moclobemide is better tolerated at therapeutic dosages and has less toxicity in overdose than TCAs and nonselective, irreversible MAO inhibitors, and is also effective in patients with a primary diagnosis of social phobia. Expand
...
1
2
...